ROCO
4117
Market cap20mUSD
Oct 08, Last price
9.39TWD
1D
9.19%
1Q
-10.57%
Jan 2017
-53.86%
IPO
27.93%
Name
General Biologicals Corp
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
General Biologicals Corporation (GBC) is a company dedicated to the research, development, production, and global commercialization of in-vitro diagnostic (IVD) solutions, operating extensively both within Taiwan and internationally. The company's core diagnostic offerings include advanced ELISA and chemiluminescence immunoassays, molecular and cellular diagnostic platforms, and rapid point-of-care testing (POCT) systems. Its diverse portfolio further encompasses COVID-19 related solutions, digital pathology, and contract development manufacturing organization (CDMO) services. Additionally, GBC provides essential blood screening services for detecting hepatitis and HIV, alongside crucial biomaterials such as antibody preparations and human plasma. Venturing beyond diagnostics, the company also markets a line of oral care products under its proprietary 'oh care' brand. These diagnostic systems are primarily utilized by clinics and laboratories. Founded in 1973, General Biologicals Corporation is headquartered in Hsinchu City, Taiwan.
Key people
Tsong Chin Lin
Chairman of the Board · since 2018
Frank Lin
General Manager, Director · since 2018
Deputy General Manager · since 2013
Jinmei Shi
Head of Finance & Accounting · since 2024
Director · since 2020
Director · since 2025
Ruixun Chen
Independent Director · since 2025
Chenghua Li
Independent Director · since 2025
Cheryl Lin
Independent Director · since 2018
Jen-Leih Wu
Independent Director · since 2018
Valuation
Title TWD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | |
| Income | |||||||
Revenues | |||||||
Cost of revenue | |||||||
Unusual Expense (Income) | |||||||
NOPBT | |||||||
NOPBT Margin | |||||||
Operating Taxes | |||||||
Tax Rate | |||||||
NOPAT | |||||||
Net income | |||||||
Dividends | |||||||
Dividend yield | |||||||
Proceeds from repurchase of equity | |||||||
BB yield | |||||||
| Debt | |||||||
Debt current | |||||||
Long-term debt | |||||||
Deferred revenue | |||||||
Other long-term liabilities | |||||||
Net debt | |||||||
| Cash flow | |||||||
Cash from operating activities | |||||||
CAPEX | |||||||
Cash from investing activities | |||||||
Cash from financing activities | |||||||
FCF | |||||||
| Balance | |||||||
Cash | |||||||
Long term investments | |||||||
Excess cash | |||||||
Stockholders' equity | |||||||
Invested Capital | |||||||
ROIC | |||||||
ROCE | |||||||
| EV | |||||||
Common stock shares outstanding | |||||||
Price | |||||||
Market cap | |||||||
EV | |||||||
EBITDA | |||||||
EV/EBITDA | |||||||
Interest | |||||||
Interest/NOPBT | |||||||